CJC-1295 with DAC is a modified GHRH analogue designed around the drug affinity complex concept. In scientific terms, the DAC feature is discussed for albumin binding and extended peptide exposure, which separates it from the shorter no-DAC version.
This product is relevant when the study question is not only GHRH receptor activity, but also how structural modification can change peptide behaviour, persistence, and endocrine-marker models. That makes it useful for comparison with CJC-1295 no-DAC, Sermorelin, and Tesamorelin.
For customers, the main thing to understand is that with-DAC and no-DAC are not interchangeable labels. The specification table gives the exact identity, sequence notation, mass, and purity of the supplied material.
The references below are starting points for the mechanisms discussed here. The specification table on this page covers identity, formula, molecular mass, physical form, solubility, storage, and lot-level analytical information.
References
- PubChem search: CJC-1295 DAC
- PubMed: CJC-1295 drug affinity complex
- PubMed: GHRH analogue receptor research
Research-use notice: Supplied strictly for lawful research, laboratory, analytical, educational, or R&D purposes where permitted by applicable law. Not for human or animal use, consumption, diagnosis, treatment, food, supplement, cosmetic, veterinary, or similar end use.
